) The specific aims of the core include the collection and storage of clinical specimens from ovarian cancer patients. These specimens include tumor tissue samples, serum, ascites, and blood lymphocytes. The collection of tissues and fluids requires the coordination of a member of Core D, the operating surgeon, and the pathologist. All tissues are delivered to the Frozen Section area of the Department of Pathology by a member of Core D. The tissue is examined and samples are provided with the provisional diagnosis. The tissues are either flash-frozen in liquid nitrogen, embedded in OCT compound, or processed in the routine manner for paraffin blocks. Some tumor specimens are placed into culture in MEM-FBS medium for the development of permanent cell lines or are explanted into SCID-nu/mice. Fresh-frozen specimens are also stored at -80 degrees Celsius for extraction of DNA and RNA. Cells in ascites fluid are either snap-frozen in liquid nitrogen or smeared onto slides. Some are also cultured in vitro or explanted into nu/nu mice. Ascites fluid and cyst fluids are stored frozen and provide sources for the isolation of mucins, growth factors and cytokines. Blood lymphocytes are separated by Hypaque and stored frozen in DMSO, Sera separated from patients? blood are also stored frozen. The core will also be responsible for staining frozen and paraffin sections of tumors from current patients to determine their eligibility to enter the radiolabeled MX35 antibody trial or with other antibodies for the vaccine trails (Project III). The core will also receive paraffin blocks from patients originally treated at extramural institutions to determine their eligibility to enter trials at MSKCC. Dr. Saigo re-reviews the pathology on all the ovarian cancer patients involved in trials in Projects 1 and 2 and on all specimens to be stored in the Tumor Bank. All tumors are classified according to histologic type and grade. Dr. Saigo also reviews any case for which the Project Leader has a question or requires additional information. Our collection of well-characterized tissue specimens, blood, and fluids is a resource used by Projects 1, 3, and 4. It is a much more efficient use of resources to have a central facility for the storage and record keeping of these samples than to have every prject collect their specimens. Moreover, Dr. Saigo is a Pathologist specializing in gynecologic cancer and her services and advice are available to investigators in all the projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA052477-12
Application #
6649935
Study Section
Project Start
2002-08-23
Project End
2003-07-31
Budget Start
Budget End
Support Year
12
Fiscal Year
2002
Total Cost
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Grisham, Rachel N; Sylvester, Brooke E; Won, Helen et al. (2015) Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer. J Clin Oncol 33:4099-105
Rao, Thapi D; Tian, Huasong; Ma, Xun et al. (2015) Expression of the Carboxy-Terminal Portion of MUC16/CA125 Induces Transformation and Tumor Invasion. PLoS One 10:e0126633
Tew, William P; Colombo, Nicoletta; Ray-Coquard, Isabelle et al. (2014) Intravenous aflibercept in patients with platinum-resistant, advanced ovarian cancer: results of a randomized, double-blind, phase 2, parallel-arm study. Cancer 120:335-43
Tsuji, Takemasa; Sabbatini, Paul; Jungbluth, Achim A et al. (2013) Effect of Montanide and poly-ICLC adjuvant on human self/tumor antigen-specific CD4+ T cells in phase I overlapping long peptide vaccine trial. Cancer Immunol Res 1:340-50
Hyman, David M; Zhou, Qin; Iasonos, Alexia et al. (2012) Improved survival for BRCA2-associated serous ovarian cancer compared with both BRCA-negative and BRCA1-associated serous ovarian cancer. Cancer 118:3703-9
Marchini, Sergio; Poynor, Elizabeth; Barakat, Richard R et al. (2012) The zinc finger gene ZIC2 has features of an oncogene and its overexpression correlates strongly with the clinical course of epithelial ovarian cancer. Clin Cancer Res 18:4313-24
Iasonos, Alexia; Sabbatini, Paul; Spriggs, David R et al. (2012) Identifying clinical improvement in consolidation single-arm phase 2 trials in patients with ovarian cancer in second or greater clinical remission. Int J Gynecol Cancer 22:63-9
Soslow, Robert A; Han, Guangming; Park, Kay J et al. (2012) Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma. Mod Pathol 25:625-36
Blixt, Ola; Lavrova, Olga I; Mazurov, Dmitriy V et al. (2012) Analysis of Tn antigenicity with a panel of new IgM and IgG1 monoclonal antibodies raised against leukemic cells. Glycobiology 22:529-42
Gardner, Ginger J; Baser, Raymond E; Brady, Mark F et al. (2012) CA125 regression in ovarian cancer patients treated with intravenous versus intraperitoneal platinum-based chemotherapy: a gynecologic oncology group study. Gynecol Oncol 124:216-20

Showing the most recent 10 out of 109 publications